Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound

Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Viruses 2024-06, Vol.16 (6)
Hauptverfasser: Erickson, Mauri, Boone, Tyler J, Nadworny, Patricia L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page
container_title Viruses
container_volume 16
creator Erickson, Mauri
Boone, Tyler J
Nadworny, Patricia L
description Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.
doi_str_mv 10.3390/v16060959
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A799645126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A799645126</galeid><sourcerecordid>A799645126</sourcerecordid><originalsourceid>FETCH-LOGICAL-g676-c9de6a42a9b08fdd0c6c42f9a87245ab0b25068507bcb4a4fbe2913d8222b30f3</originalsourceid><addsrcrecordid>eNptjE1LxDAYhIMouK4e_AcBr7a-TZO077EWVxcW9uB6kmVJ0qRE-qH9Av-99eOwB5nDPAwzQ8h1BGEcI9xNkQQJKPCELCJEDDhG4vSIz8lF378BSImQLMh91gx-8p2qaGa-afikraNZ-dqPOhT79fYH5P6WKvrS-I_R0mdfTbajeVu_t2NTXJIzp6reXv35kuxWD7v8KdhsH9d5tglKmcjAYGGl4kyhhtQVBRhpOHOo0oRxoTRoJkCmAhJtNFfcacswiouUMaZjcPGS3PzelqqyB9-4duiUqX1vDlmCKLmImJxb4T-tWYWtvWkb6_ycHw2-AN7KWPU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</creator><creatorcontrib>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</creatorcontrib><description>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</description><identifier>ISSN: 1999-4915</identifier><identifier>EISSN: 1999-4915</identifier><identifier>DOI: 10.3390/v16060959</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Antiviral agents ; Care and treatment ; Communicable diseases ; Complications and side effects ; Diagnosis ; Drug resistance in microorganisms ; Evaluation ; Patient outcomes ; Public health administration</subject><ispartof>Viruses, 2024-06, Vol.16 (6)</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Erickson, Mauri</creatorcontrib><creatorcontrib>Boone, Tyler J</creatorcontrib><creatorcontrib>Nadworny, Patricia L</creatorcontrib><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><title>Viruses</title><description>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</description><subject>Antiviral agents</subject><subject>Care and treatment</subject><subject>Communicable diseases</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Drug resistance in microorganisms</subject><subject>Evaluation</subject><subject>Patient outcomes</subject><subject>Public health administration</subject><issn>1999-4915</issn><issn>1999-4915</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjE1LxDAYhIMouK4e_AcBr7a-TZO077EWVxcW9uB6kmVJ0qRE-qH9Av-99eOwB5nDPAwzQ8h1BGEcI9xNkQQJKPCELCJEDDhG4vSIz8lF378BSImQLMh91gx-8p2qaGa-afikraNZ-dqPOhT79fYH5P6WKvrS-I_R0mdfTbajeVu_t2NTXJIzp6reXv35kuxWD7v8KdhsH9d5tglKmcjAYGGl4kyhhtQVBRhpOHOo0oRxoTRoJkCmAhJtNFfcacswiouUMaZjcPGS3PzelqqyB9-4duiUqX1vDlmCKLmImJxb4T-tWYWtvWkb6_ycHw2-AN7KWPU</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Erickson, Mauri</creator><creator>Boone, Tyler J</creator><creator>Nadworny, Patricia L</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20240601</creationdate><title>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</title><author>Erickson, Mauri ; Boone, Tyler J ; Nadworny, Patricia L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g676-c9de6a42a9b08fdd0c6c42f9a87245ab0b25068507bcb4a4fbe2913d8222b30f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral agents</topic><topic>Care and treatment</topic><topic>Communicable diseases</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Drug resistance in microorganisms</topic><topic>Evaluation</topic><topic>Patient outcomes</topic><topic>Public health administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erickson, Mauri</creatorcontrib><creatorcontrib>Boone, Tyler J</creatorcontrib><creatorcontrib>Nadworny, Patricia L</creatorcontrib><jtitle>Viruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erickson, Mauri</au><au>Boone, Tyler J</au><au>Nadworny, Patricia L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound</atitle><jtitle>Viruses</jtitle><date>2024-06-01</date><risdate>2024</risdate><volume>16</volume><issue>6</issue><issn>1999-4915</issn><eissn>1999-4915</eissn><abstract>Pentasilver hexaoxoiodate (Ag[sub.5] IO[sub.6] ) has broad-spectrum antimicrobial efficacy, including the long-term prevention of microbial adherence, the rapid killing of planktonic microorganisms, and the elimination of mature biofilms. This study’s goal was to determine whether it may also have antiviral activity against structurally distinct viruses. Ag[sub.5] IO[sub.6] was tested following ASTM E1052-20, Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension, against adenovirus type 5, murine norovirus, poliovirus type 1, SARS-CoV-2 (original), and SARS-CoV-2 (omicron) (host cells: H1HeLa, RAW 264.7, LLC-MK2, Vero E6, and Vero E6, respectively). A 0.1 g/mL Ag[sub.5] IO[sub.6] suspension was prepared and the viruses were exposed for 30 min, 4 h, or 24 h. Exposure to Ag[sub.5] IO[sub.6] resulted in complete kill of SARS-CoV-2 (omicron) within 30 min, as well as complete kill of both SARS-CoV-2 (original) and the murine norovirus within 4 h. Ag[sub.5] IO[sub.6] showed increasing activity over time against the adenovirus, but did not achieve a 3-log reduction within 24 h, and showed no antiviral activity against the poliovirus. These results demonstrate that Ag[sub.5] IO[sub.6] has antiviral activity against medically important viruses, in addition to its well-characterized antimicrobial activity, suggesting that it may be valuable in situations where the prevention or simultaneous treatment of microbes and viruses are necessary.</abstract><pub>MDPI AG</pub><doi>10.3390/v16060959</doi></addata></record>
fulltext fulltext
identifier ISSN: 1999-4915
ispartof Viruses, 2024-06, Vol.16 (6)
issn 1999-4915
1999-4915
language eng
recordid cdi_gale_infotracmisc_A799645126
source MDPI - Multidisciplinary Digital Publishing Institute; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access
subjects Antiviral agents
Care and treatment
Communicable diseases
Complications and side effects
Diagnosis
Drug resistance in microorganisms
Evaluation
Patient outcomes
Public health administration
title Antiviral Activity of Ag[sub.5]IO[sub.6], a Unique Silver Compound
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A14%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20Activity%20of%20Ag%5Bsub.5%5DIO%5Bsub.6%5D,%20a%20Unique%20Silver%20Compound&rft.jtitle=Viruses&rft.au=Erickson,%20Mauri&rft.date=2024-06-01&rft.volume=16&rft.issue=6&rft.issn=1999-4915&rft.eissn=1999-4915&rft_id=info:doi/10.3390/v16060959&rft_dat=%3Cgale%3EA799645126%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A799645126&rfr_iscdi=true